How much did Globeimmune achieve in EBIT for the current year?
In the current year, Globeimmune has achieved an EBIT of -2.77 M USD.
Globeimmune EBIT 2024
Globeimmune EBIT
-2.77 M USD
Ticker
GBIM
ISIN
US37957B1008
WKN
A1J41J
In 2024, Globeimmune's EBIT was -2.77 M USD, a -52.45% increase from the -5.82 M USD EBIT recorded in the previous year.
The Globeimmune EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2015 | -2.77 |
| 2014 | -5.82 |
| 2013 | 7.69 |
| 2012 | -3.97 |
| 2011 | -12.59 |
| 2010 | -15.75 |
| 2009 | -20.38 |
| 2008 | -29.11 |
| 2007 | -19.8 |
Globeimmune Revenue, EBIT, Net Income US37957B1008 · A1J41J
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Globeimmune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Globeimmune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Globeimmune’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Globeimmune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Globeimmune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Globeimmune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Globeimmune’s growth potential.
Globeimmune Revenue, EBIT and net profit per share
| Date | Globeimmune Revenue | Globeimmune EBIT | Globeimmune Net Income |
|---|---|---|---|
| 2015 | 6.46 M undefined | -2.77 M undefined | -2.77 M undefined |
| 2014 | 5.97 M undefined | -5.82 M undefined | -23.43 M undefined |
| 2013 | 22.52 M undefined | 7.69 M undefined | -3.41 M undefined |
| 2012 | 14.64 M undefined | -3.97 M undefined | -14.12 M undefined |
| 2011 | 5.11 M undefined | -12.59 M undefined | -25.04 M undefined |
| 2010 | 4.07 M undefined | -15.75 M undefined | -25.36 M undefined |
| 2009 | 2.54 M undefined | -20.38 M undefined | -30.54 M undefined |
| 2008 | 0 undefined | -29.11 M undefined | -36.32 M undefined |
| 2007 | 0 undefined | -19.8 M undefined | -24.66 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 0 USD | -19.8 M USD | -24.66 M USD |
| 2008 | 0 USD | -29.11 M USD | -36.32 M USD |
| 2009 | 2.54 M USD | -20.38 M USD | -30.54 M USD |
| 2010 | 4.07 M USD | -15.75 M USD | -25.36 M USD |
| 2011 | 5.11 M USD | -12.59 M USD | -25.04 M USD |
| 2012 | 14.64 M USD | -3.97 M USD | -14.12 M USD |
| 2013 | 22.52 M USD | 7.69 M USD | -3.41 M USD |
| 2014 | 5.97 M USD | -5.82 M USD | -23.43 M USD |
| 2015 | 6.46 M USD | -2.77 M USD | -2.77 M USD |
Globeimmune stock margins US37957B1008 · A1J41J
The Globeimmune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Globeimmune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Globeimmune.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Globeimmune's sales revenue. A higher gross margin percentage indicates that the Globeimmune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Globeimmune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Globeimmune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Globeimmune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Globeimmune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Globeimmune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Globeimmune Margin History
| Globeimmune Gross margin | Globeimmune Profit margin | Globeimmune EBIT margin | Globeimmune Profit margin |
|---|---|---|---|
| 2015 | 95.54 % | -42.85 % | -42.85 % |
| 2014 | 74.19 % | -97.53 % | -392.78 % |
| 2013 | 85.93 % | 34.14 % | -15.14 % |
| 2012 | 100 % | -27.09 % | -96.43 % |
| 2011 | 95.54 % | -246.55 % | -490.25 % |
| 2010 | 95.54 % | -387.31 % | -623.33 % |
| 2009 | 95.54 % | -802.36 % | -1,202.36 % |
| 2008 | 95.54 % | 0 % | 0 % |
| 2007 | 95.54 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 95.54 % | 0 % | 0 % |
| 2008 | 95.54 % | 0 % | 0 % |
| 2009 | 95.54 % | -802.36 % | -1,202.36 % |
| 2010 | 95.54 % | -387.31 % | -623.33 % |
| 2011 | 95.54 % | -246.55 % | -490.25 % |
| 2012 | 100 % | -27.09 % | -96.43 % |
| 2013 | 85.93 % | 34.14 % | -15.14 % |
| 2014 | 74.19 % | -97.53 % | -392.78 % |
| 2015 | 95.54 % | -42.85 % | -42.85 % |
Globeimmune Aktienanalyse
What does Globeimmune do?
Globeimmune Inc. is a biopharmaceutical company that focuses on the development of immunotherapies for various types of cancer. The company was founded in 1998 in Louisville, Colorado, USA, and went public in 2014. Globeimmune's business model revolves around the use of its patented Tarmogen technology, which aims to activate the immune system against cancer cells. The company has conducted clinical studies for its treatments targeting pancreatic, lung, and prostate cancer. Globeimmune has also formed partnerships with other pharmaceutical companies, including one with Sanko Junyaku in Japan to market its Tarmogen technology in Asia. The company's product range includes various immunotherapies based on the Tarmogen technology, such as GI-4000 for pancreatic cancer, GI-6207 for prostate cancer, and GI-6301 for lung cancer. Globeimmune has achieved success in recent years, including completing a financing round of $15.6 million in 2012 and going public with a $35 million IPO in 2014. Overall, Globeimmune is a promising biopharmaceutical company that focuses on developing effective immunotherapies for cancer patients using its Tarmogen technology, which has the potential to revolutionize cancer treatment and provide patients with effective and gentle therapies. Globeimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Globeimmune's EBIT
Globeimmune's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Globeimmune's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Globeimmune's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Globeimmune’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Globeimmune stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Globeimmune.
How has the EBIT of Globeimmune developed in recent years?
The EBIT of Globeimmune has increased by -52.451% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Globeimmune?
The EBIT of Globeimmune is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Globeimmune pay?
Over the past 12 months, Globeimmune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Globeimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Globeimmune?
The current dividend yield of Globeimmune is .
When does Globeimmune pay dividends?
Globeimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Globeimmune?
Globeimmune paid dividends every year for the past 0 years.
What is the dividend of Globeimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Globeimmune located?
Globeimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Globeimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Globeimmune from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.
When did Globeimmune pay the last dividend?
The last dividend was paid out on 10/25/2024.
What was the dividend of Globeimmune in the year 2023?
In the year 2023, Globeimmune distributed 0 USD as dividends.
In which currency does Globeimmune pay out the dividend?
The dividends of Globeimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Globeimmune
Our stock analysis for Globeimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Globeimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
